エラスカ
Erasca, Inc.
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | -0.14 | $0 | -$27M |
| 2026 Q1 | -0.60 | $0 | -$27M |
| 2025 Q4 | -0.10 | $0 | -$22M |
| 2025 Q3 | -0.11 | $0 | -$22M |
| 2025 Q2 | -0.12 | $0 | -$21M |
| 2025 Q1 | -0.11 | $0 | -$32M |
| 2024 Q4 |
| -0.11 |
| $0 |
| -$25M |
| 2024 Q3 | -0.11 | $0 | -$22M |